# OnCo record cr-001 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cr-001/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cr-001" ;
  schema:name "CR-001"@en ;
  schema:alternateName "SKB118"@en ;
  schema:description "CR-001 is an experimental tetravalent bispecific antibody from Crescent Biopharma, in phase 2 trials for non-small cell lung cancer and advanced solid tumours."@en ;
  schema:url <https://onco.cc/drugs/cr-001/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.crescentbiopharma.com/pipeline>, <https://www.crescentbiopharma.com/pipeline>, <https://www.crescentbiopharma.com/pipeline>, <https://clinicaltrials.gov/api/v2/studies/NCT07586943>, <https://clinicaltrials.gov/search?intr=CR-001> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Tetravalent bispecific antibody" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/crescent-biopharma/>, <https://onco.cc/companies/kelun-biotech/> ;
  onco:trials <https://onco.cc/trials/nct07335497/>, <https://onco.cc/trials/nct07586943/>, <https://onco.cc/trials/nct07697586/>, <https://onco.cc/trials/nct07854509/> .